百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BGNE 百济神州

盘前交易 04-23 04:50:53 EDT

130.94

+1.42

+1.10%

盘前133.58

+2.64+2.02%

04:46 EDT

最高133.09	最低129.96	成交量15.26万
今开130.55	昨收129.52	日振幅2.42%
总市值136.82亿	流通市值76.74亿	总股本1.04亿
成交额2,006万	换手率0.26%	流通股本5,861万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BGNE","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":130.94,"timestamp":1713816000000,"preClose":129.52,"halted":0,"volume":152563,"hourTrading":{"tag":"盘前","latestPrice":133.58,"preClose":130.94,"latestTime":"04:46 EDT","volume":17,"amount":2270.86,"timestamp":1713861977514},"delay":0,"floatShares":58607752,"shares":104490318,"eps":-8.446508,"marketStatus":"盘前交易","marketStatusCode":1,"change":1.42,"latestTime":"04-23 04:50:53 EDT","open":130.55,"high":133.09,"low":129.96,"amount":20059405.83951,"amplitude":0.024166,"askPrice":142.5,"askSize":50,"bidPrice":133.55,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-8.446508,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713879000000},"adr":1,"adjPreClose":130.94,"adrRate":13,"preHourTrading":{"tag":"盘前","latestPrice":133.58,"preClose":130.94,"latestTime":"04:46 EDT","volume":17,"amount":2270.86,"timestamp":1713861977514},"postHourTrading":{"tag":"盘后","latestPrice":130.94,"preClose":130.94,"latestTime":"16:05 EDT","volume":2858,"amount":374226.09,"timestamp":1713816346107},"volumeRatio":0.6578452625413039},"requestUrl":"/m/hq/s/BGNE","defaultTab":"news","newsList":[{"id":"2429872531","title":"南向资金4月22日净买入百济神州25.34万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2429872531","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429872531?lang=zh_cn&edition=full","pubTime":"2024-04-23 09:31","pubTimestamp":1713835874,"startTime":"0","endTime":"0","summary":"4月22日, 南向资金增持百济神州25.34万股，连续3日增持。截止当日收盘，港股通共持有百济神州5257.94万股，占流通股3.85%。百济神州近5个交易日下跌5.18%，港股通累计增持31.63万股；近20个交易日下跌22.37%，港股通累计增持216.90万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042309473187a38916&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042309473187a38916&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428520381","title":"百济神州获融资买入0.13亿元，近三日累计买入0.29亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428520381","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2428520381?lang=zh_cn&edition=full","pubTime":"2024-04-19 08:21","pubTimestamp":1713486102,"startTime":"0","endTime":"0","summary":"4月18日，沪深两融数据显示，百济神州获融资买入额0.13亿元，居两市第601位，当日融资偿还额0.06亿元，净买入707.20万元。最近三个交易日，16日-18日，百济神州分别获融资买入0.06亿元、0.10亿元、0.13亿元。融券方面，当日融券卖出0.54万股，净买入0.59万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190821478792723c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190821478792723c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428058981","title":"营收达178亿，百济神州逆势加码！创新药的春天来了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2428058981","media":"侃见财经","top":-1,"share":"https://www.laohu8.com/m/news/2428058981?lang=zh_cn&edition=full","pubTime":"2024-04-18 10:04","pubTimestamp":1713405851,"startTime":"0","endTime":"0","summary":"且在27家生物医药类的上市公司当中，仅有8家公司IPO募资金额超过了10亿元。百济神州在年报中提到，公司营业收入增加主要得益于核心市场产品销售额的增长。其中百悦泽全球销售额达13亿美元，突破十亿美元大关。值得注意的是，百悦泽的成功，让百济神州成功的摆脱了资金困境，根据财报显示，截至2023年末公司期末现金、现金等价物及受限现金31.86亿美元。受此影响，百济神州的股价在创新药行业当中，一直比较坚挺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418100944878cb300&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418100944878cb300&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428583817","title":"北向资金4月17日净买入百济神州-U4.82万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2428583817","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428583817?lang=zh_cn&edition=full","pubTime":"2024-04-18 09:30","pubTimestamp":1713403830,"startTime":"0","endTime":"0","summary":"4月17日, 北向资金增持百济神州-U4.82万股，连续5日增持。截止当日收盘，沪股通共持有百济神州-U538.87万股，占流通股4.68%。沪股通增持金额前五个股分别为国电电力、大秦铁路、同仁堂、中国平安、赤峰黄金。百济神州-U近5个交易日下跌8.50%，沪股通累计增持12.65万股；近20个交易日下跌14.09%，沪股通累计增持47.74万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180935218b3248a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180935218b3248a0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427850430","title":"南向资金4月15日净买入百济神州23.99万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2427850430","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427850430?lang=zh_cn&edition=full","pubTime":"2024-04-16 09:31","pubTimestamp":1713231090,"startTime":"0","endTime":"0","summary":"4月15日, 南向资金增持百济神州23.99万股，连续3日增持。截止当日收盘，港股通共持有百济神州5226.30万股，占流通股3.84%。百济神州近5个交易日下跌6.72%，港股通累计增持27.33万股；近20个交易日下跌19.00%，港股通累计增持364.33万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160943538781e7cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160943538781e7cf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427850259","title":"北向资金4月15日净买入百济神州-U1.57万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2427850259","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427850259?lang=zh_cn&edition=full","pubTime":"2024-04-16 09:30","pubTimestamp":1713231036,"startTime":"0","endTime":"0","summary":"4月15日, 北向资金增持百济神州-U1.57万股，连续3日增持。截止当日收盘，沪股通共持有百济神州-U531.20万股，占流通股4.61%。沪股通增持金额前五个股分别为贵州茅台、中国建筑、山西汾酒、兴业银行、招商银行。百济神州-U近5个交易日下跌2.38%，沪股通累计增持24.74万股；近20个交易日下跌10.75%，沪股通累计增持128.51万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160935088781df2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160935088781df2d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427853720","title":"百济神州(06160)：建议授予董事受限制股份单位及业绩股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2427853720","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2427853720?lang=zh_cn&edition=full","pubTime":"2024-04-16 07:37","pubTimestamp":1713224265,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州 发布公告，董事会已议决根据2016年计划建议授予受限制股份单位及业绩股份单位如下，但须获接纳及于股东周年大会上获独立股东批准方可作实：授予欧雷强先生于授予日期公平值为600万美元的受限制股份单位;授予欧雷强先生于授予日期公平值为600万美元的业绩股份单位;授予王晓东博士于授予日期公平值为133.33万美元的受限制股份单位;及授予各独立非执行董事于授予日期公平值为20万美元的受限制股份单位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103026.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427921044","title":"百济神州（上海）生物科技有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2427921044","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2427921044?lang=zh_cn&edition=full","pubTime":"2024-04-15 15:02","pubTimestamp":1713164560,"startTime":"0","endTime":"0","summary":"4月15日，据CDE官网消息，百济神州(上海)生物科技有限公司联合申请药品“替雷利珠单抗注射液”，获得临床试验默示许可，受理号CXSB2400009。公示信息显示，药品“替雷利珠单抗注射液”适应症：替雷利珠单抗联合Ociperlimab用于非小细胞肺癌的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415150523877e3b04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415150523877e3b04&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426692332","title":"百济神州下跌2.18%，报146.5美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426692332","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426692332?lang=zh_cn&edition=full","pubTime":"2024-04-11 22:56","pubTimestamp":1712847394,"startTime":"0","endTime":"0","summary":"4月11日，百济神州(BGNE)盘中下跌2.18%，截至22:56，报146.5美元/股，成交903.48万美元。财务数据显示，截至2023年12月31日，百济神州收入总额24.59亿美元，同比增长73.65%；归母净利润-8.82亿美元，同比增长56.0%。大事提醒：4月8日，百济神州获美国银行下调目标价至164.3美元，最新评级Neutral。5月2日，百济神州将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/11225640205824.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426066224","title":"百济神州(06160)下跌5.04%，报88.5元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426066224","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426066224?lang=zh_cn&edition=full","pubTime":"2024-04-11 11:22","pubTimestamp":1712805723,"startTime":"0","endTime":"0","summary":"4月11日，百济神州(06160)盘中下跌5.04%，截至11:22，报88.5元/股，成交4451.78万元。百济神州有限公司是一家专注于开发和商业化用于治疗癌症的创新型分子靶向和肿瘤免疫治疗药物的生物技术公司。公司拥有包括六种内部开发的临床阶段候选药物和五种获得授权许可的药物在内的广泛产品组合，以及超过1300名员工的全球团队。截至2023年年报，百济神州营业总收入174.15亿元、净利润-62.45亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/11112240195394.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426593406","title":"百济神州(06160)股价下跌5.043%，现价港币$88.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2426593406","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2426593406?lang=zh_cn&edition=full","pubTime":"2024-04-11 11:20","pubTimestamp":1712805600,"startTime":"0","endTime":"0","summary":"[下跌股]百济神州(06160) 股价在上午11:20比前收市价下跌5.043%，现股价为港币$88.5。至目前为止，今日最高价为$90.6，而最低价为$88.5。总成交量为47.68万股，总成交金额为港币$4.272千万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD240411964/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2426048188","title":"《大行》美银证券降百济神州(06160.HK)目标价至99.21元  评级“中性”","url":"https://stock-news.laohu8.com/highlight/detail?id=2426048188","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2426048188?lang=zh_cn&edition=full","pubTime":"2024-04-10 12:01","pubTimestamp":1712721660,"startTime":"0","endTime":"0","summary":"美银证券发表研究报告指，百济神州自研药物帕米帕利2月销售额为60万元人民币，按年跌27.8%，按月跌43.2%，而替雷利珠单抗、Zanubrutinib的销售额则分别为1.609亿和4,470万元人民币，按年增长51.9%及26.4%，按月则降31%及32%。2月药品销售按月下降主要是受到农历新年的影响。该行表示，鉴于中国市场上PARP抑制剂和其他生物类似药产品的激烈竞争，将目标价由108.27元下调至99.21元，并重申“中性”评级。(港股报价延迟最少十五分钟。沽空资料截至 2024-04-09 16:25。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20210201153351459_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20210201153351459_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1341255/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2426105895","title":"百济神州-U4月9日获北向资金加仓25.15万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426105895","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426105895?lang=zh_cn&edition=full","pubTime":"2024-04-10 09:30","pubTimestamp":1712712637,"startTime":"0","endTime":"0","summary":"4月9日, 北向资金增持百济神州-U25.15万股，连续4日增持。截止当日收盘，沪股通共持有百济神州-U531.61万股，占流通股4.62%。沪股通增持金额前五个股分别为紫金矿业、海尔智家、赤峰黄金、中金黄金、洛阳钼业。百济神州-U近5个交易日下跌1.30%，沪股通累计增持47.79万股；近20个交易日上涨2.97%，沪股通累计增持227.56万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404100935168b064b35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404100935168b064b35&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426113306","title":"百济神州上涨2.47%，报153.45美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426113306","media":"金融界网站","top":-1,"share":"https://www.laohu8.com/m/news/2426113306?lang=zh_cn&edition=full","pubTime":"2024-04-09 22:21","pubTimestamp":1712672517,"startTime":"0","endTime":"0","summary":"转自：金融界本文源自:金融界4月9日，百济神州(BGNE)盘中上涨2.47%，截至22:00，报153.45美元/股，成交173.16万美元。财务数据显示，截至2023年12月31日，百济神州收入总额24.59亿美元，同比增长73.65%；归母净利润-8.82亿美元，同比增长56.0%。大事提醒：4月8日，百济神州获美国银行下调目标价至164.3美元，最新评级Neutral。5月2日，百济神州将披露2024财年一季报。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404092222038b03bf94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404092222038b03bf94&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426184735","title":"肿瘤创新药“广州造”，粤港澳大湾区首个ADC生产基地启用","url":"https://stock-news.laohu8.com/highlight/detail?id=2426184735","media":"南方都市报","top":-1,"share":"https://www.laohu8.com/m/news/2426184735?lang=zh_cn&edition=full","pubTime":"2024-04-09 12:14","pubTimestamp":1712636046,"startTime":"0","endTime":"0","summary":"4月8日，创新药企百济神州位于中新广州知识城的广州大分子生物药生产基地抗体偶联药物生产园区竣工启用，这不仅是广州第一个、也是粤港澳大湾区的首个ADC生产基地。位于广州生物药生产基地南园的ADC生产园区，占地5.8万平方米，将成为百济神州ADC药物研发和生产的核心基地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091215578b0141dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091215578b0141dc&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426861909","title":"北向资金4月8日净买入百济神州-U12.67万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2426861909","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426861909?lang=zh_cn&edition=full","pubTime":"2024-04-09 09:30","pubTimestamp":1712626238,"startTime":"0","endTime":"0","summary":"4月8日, 北向资金增持百济神州-U12.67万股，连续3日增持。截止当日收盘，沪股通共持有百济神州-U506.46万股，占流通股4.40%。沪股通增持金额前五个股分别为海尔智家、山西汾酒、兴业银行、韦尔股份、工商银行。百济神州-U近5个交易日下跌2.79%，沪股通累计增持21.60万股；近20个交易日上涨1.79%，沪股通累计增持233.74万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090936458756a0af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090936458756a0af&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426908938","title":"ADC药物代工在兴起，缘何这家药企选择自建生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2426908938","media":"第一财经","top":-1,"share":"https://www.laohu8.com/m/news/2426908938?lang=zh_cn&edition=full","pubTime":"2024-04-09 08:57","pubTimestamp":1712624245,"startTime":"0","endTime":"0","summary":"抗体偶联药物研发火热，正在催生代工厂兴起，不过，仍有药企选择自建生产基地。据介绍，该园区占地5.8万平方米，将成为百济神州ADC药物研发和生产的核心基地。根据智慧芽新药情报库，在中国开展的ADC药物临床试验超过1000项，涉及药企超过百家。ADC药物的生产投入，远高于抗体类药物。公司凭借全球肿瘤学领域的专业研究团队以及端到端的ADC生产能力，为公司的创新药物研发与生产奠定了坚实基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090858377a517cb3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090858377a517cb3&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426971291","title":"百济神州获北向资金买入1619.44万元，累计持股506.46万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426971291","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426971291?lang=zh_cn&edition=full","pubTime":"2024-04-09 07:51","pubTimestamp":1712620301,"startTime":"0","endTime":"0","summary":"4月9日，巨灵财经数据显示，北向资金8日增持百济神州预估1619.44万元，累计持股506.46万股，总计持有市值6.44亿元，占流通股比例4.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090751438b005604&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090751438b005604&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426908891","title":"广州又一重磅生物药基地竣工启用 发力“抗癌生物导弹”开发生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2426908891","media":"羊城晚报","top":-1,"share":"https://www.laohu8.com/m/news/2426908891?lang=zh_cn&edition=full","pubTime":"2024-04-09 07:03","pubTimestamp":1712617439,"startTime":"0","endTime":"0","summary":"羊城晚报讯记者陈泽云报道：4月8日，全球肿瘤创新公司百济神州宣布，位于广州中新知识城的抗体偶联药物（ADC）生产园区竣工启用。依托该基地，百济神州将启动有着“抗癌生物导弹”之称的ADC药物的开发和生产工作，面向全球患者研发和输出更多“广州造”创新药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404093037041796.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426945205","title":"B of A Securities：维持百济神州(BGNE.US)评级，由中性调整至中性评级, 目标价由179.30美元调整至164.30美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2426945205","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426945205?lang=zh_cn&edition=full","pubTime":"2024-04-09 00:44","pubTimestamp":1712594647,"startTime":"0","endTime":"0","summary":"B of A Securities：维持百济神州(BGNE.US)评级，由中性调整至中性评级, 目标价由179.30美元调整至164.30美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090044108aff5087&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090044108aff5087&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beigene.cn","stockEarnings":[{"period":"1week","weight":-0.0539},{"period":"1month","weight":-0.1387},{"period":"3month","weight":-0.1931},{"period":"6month","weight":-0.2135},{"period":"1year","weight":-0.4934},{"period":"ytd","weight":-0.274}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0412},{"period":"3month","weight":0.0306},{"period":"6month","weight":0.1968},{"period":"1year","weight":0.2123},{"period":"ytd","weight":0.0514}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BeiGene Ltd是一家全球生物技术公司，致力于为全球癌症患者发现和开发肿瘤治疗方法。该公司已发现并开发三种批准药物，包括BRUKINSA，一种布鲁顿酪氨酸激酶的小分子抑制剂，用于治疗各种血癌；TEVIMBRA（tislelizumab），一种抗PD-1抗体免疫疗法，用于治疗各种实体瘤和血癌；以及是聚ADP核糖聚合酶1(PARP1)和PARP2的选择性小分子抑制剂pamiparib。该公司已获得在美国、中华人民共和国（中国）、欧盟、英国、加拿大、澳大利亚和其他国际市场销售BRUKINSA，在欧盟和中国销售替雷利珠单抗，以及在中国销售帕米帕尼的批准。它还专注于在Amgen Inc独家授权下在中国商业化癌症药物，如XGEVA、BLINCYTO、KYPROLIS等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.062331},{"month":2,"riseRate":0.625,"avgChangeRate":0.017001},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.028933},{"month":4,"riseRate":0.444444,"avgChangeRate":0.012358},{"month":5,"riseRate":0.5,"avgChangeRate":-0.012888},{"month":6,"riseRate":0.625,"avgChangeRate":0.022561},{"month":7,"riseRate":0.75,"avgChangeRate":0.132564},{"month":8,"riseRate":0.5,"avgChangeRate":0.021799},{"month":9,"riseRate":0.5,"avgChangeRate":0.051436},{"month":10,"riseRate":0.625,"avgChangeRate":0.017618},{"month":11,"riseRate":0.5,"avgChangeRate":0.059889},{"month":12,"riseRate":0.375,"avgChangeRate":-0.023463}],"exchange":"NASDAQ","name":"百济神州","nameEN":"BeiGene"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(BGNE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,BGNE,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(BGNE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}